And, although I’m not at SABCS this year, why do we not have data on TILS from KN522?!

Not at SABCS, but from afar there has to be some positive biomarkers from a trial where a significant minority don’t seem to benefit (in terms of pathCR at least) from treatment. More work needed!

I should also add that regulators have a key role here and there are signs that requirements will change. We need to using prognostic biomarkers (eg path response) and balancing the harm versus benefit of these treatments for both patients and health care systems

Same comment as on the other forum!

I really like this paper and remember being impresssed when it was presented. Hats off to the authors!

It’s the best CME there is. Shame you can’t claim the time!

Certainly needs unpicking and hopefully the samples exist to do that. Did the trial contain a cytotoxic back bone? If not, I wonder if this is needed. Seemingly lots of potential but so far a complex story with anti-TIGIT molecules

I’m at 2 rejections for what we feel is a practice changing study. One likely ‘out of scope’, 2nd too expensive and not enough evidence of community support (multiple surveys/patient focus groups backing). Hopeful plan c being made today but it is quite exhausting!

Feel your pain. Can feel like a brick wall. But, celebrate your (very obvious) successes and remember you’re doing great and your research will make a difference!

I’ll await my invite..

Not attending this year sadly!

Feel free to please add me Mike

Indeed, also not without controversy I think due to AI results but more relevant than ever due to ⬆️ use. However, I’ve seen critiques of the adherence in the trial and ⬆️vaginal oestrogen doses used that are much higher than modern preparations. Always ➕/➖ when discussing with pts

Bravo, great paper. Lots of emerging data for the PD1/TIGIT combo in the lab but data from lung trials has been disappointing. I hope that new strategies, with chemo or ADC backbones, may help circumvent this resistance. We know cytotoxics induce CSCs and it needs exploring

ALSPAC in Bristol?

@ptarantinomd.bsky.social? ☝️